文献速递肿瘤 PET/CT

68Ga-FAPI-04与18F-FDG PET/CT在延胡索酸水合酶缺陷型肾细胞癌中的比较:一项前瞻性单中心研究

Comparison of 68 Ga-FAPI-04 and 18 F-FDG PET/CT in Fumarate Hydratase-Deficient Renal Cell Carcinoma : A Prospective and Single-Center Study.
PubMed 文献 · Clin Nucl Med · 2024-07-03

该前瞻性单中心研究纳入11例延胡索酸水合酶缺陷型肾细胞癌(FHRCC)患者共83个病灶,比较68Ga-FAPI-04与18F-FDG PET/CT的诊断价值;18F-FDG PET/CT检出原发及转移灶的比率高于68Ga-FAPI-04,但68Ga-FAPI-04的肿瘤/肝脏比值(TLR)更高,可能提示靶向成纤维细胞活化蛋白的治疗潜力。

要点

  • 18F-FDG PET/CT检出FHRCC病灶的比率高于68Ga-FAPI-04 PET/CT。
  • 两种示踪剂在病灶的SUVmax上无显著差异。
  • 68Ga-FAPI-04 PET/CT的TLR高于18F-FDG PET/CT。

核心结论

  • 18F-FDG PET/CT检出的原发和转移性FHRCC病灶多于68Ga-FAPI-04 PET/CT。
  • 68Ga-FAPI-04 PET/CT在FHRCC中较高的TLR可能提示靶向成纤维细胞活化蛋白的治疗潜力。

研究设计与样本

  • 前瞻性单中心研究,纳入2022年5月至2023年12月接受68Ga-FAPI-04和18F-FDG PET/CT的FHRCC患者。
  • 共纳入11例患者、83个病灶,采用Wilcoxon符号秩检验比较两种示踪剂的SUVmax和肿瘤/肝脏比值(TLR)。

主要发现

  • 18F-FDG PET/CT检出病灶的比率高于68Ga-FAPI-04 PET/CT:原发肿瘤75.0%(6/8)vs 50.0%(4/8);淋巴结94.9%(37/39)vs 89.7%(35/39);骨病灶100.0%(21/21)vs 90.5%(19/21)。
  • 原发和转移灶在18F-FDG PET/CT与68Ga-FAPI-04 PET/CT上的中位SUVmax相当:原发灶13.86 vs 16.35(P=1.000);淋巴结10.04 vs 9.33(P=0.517);骨病灶13.49 vs 9.84(P=0.107);内脏病灶8.54 vs 4.20(P=0.056)。
  • 68Ga-FAPI-04 PET/CT的原发和转移灶中位TLR高于18F-FDG PET/CT:原发灶30.44 vs 5.41(P=0.010);淋巴结17.71 vs 3.95(P=0.000);骨病灶15.94 vs 5.21(P=0.000);内脏病灶9.26 vs 3.44(P=0.003)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Fumarate hydratase-deficient renal cell cancer (FHRCC) is a rare and aggressive form of renal cell carcinoma. The diagnostic value of 68 Ga-FAPI PET/CT for FHRCC remains unexplored. Therefore, we compared the potential value of 68 Ga-FAPI-04 and 18 F-FDG PET/CT in FHRCC. PATIENTS AND METHODS: Patients with FHRCC underwent 68 Ga-FAPI-04 and 18 F-FDG PET/CT from May 2022 to December 2023. The SUV max and tumor-to-liver ratio (TLR) of both tracers were compared using the Wilcoxon signed rank test. RESULTS: Eleven patients with 83 lesions were enrolled. The rate of 18 F-FDG PET/CT in detecting lesions was higher than that of 68 Ga-FAPI-04 PET/CT: primary tumors: 75.0% (6/8) versus 50.0% (4/8); lymph nodes: 94.9% (37/39) versus 89.7% (35/39); and bone lesions: 100.0% (21/21) versus 90.5% (19/21). The median SUV max of primary and metastatic lesions on 18 F-FDG PET/CT was comparable to 68 Ga-FAPI-04 PET/CT in semiquantitative analysis (primary lesions: 13.86 vs 16.35, P = 1.000; lymph nodes: 10.04 vs 9.33, P = 0.517; bone lesions: 13.49 vs 9.84, P = 0.107; visceral lesions: 8.54 vs 4.20, P = 0.056). However, the median TLRs of primary and metastatic lesions on 68 Ga-FAPI-04 PET/CT were higher than that of 18 F-FDG PET/CT (primary lesions: 30.44 vs 5.41, P = 0.010; lymph nodes: 17.71 vs 3.95, P = 0.000; bone lesions: 15.94 vs 5.21, P = 0.000; visceral lesions: 9.26 vs 3.44, P = 0.003). CONCLUSIONS: 18 F-FDG PET/CT detected more primary and metastatic FHRCC lesions than 68 Ga-FAPI-04 PET/CT. However, the higher TLR in FHRCC on 68 Ga-FAPI-04 PET/CT may indicate therapeutic potential in targeting fibroblast activation protein in FHRCC.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Huang S, Liu H, Dai H, et al. Comparison of 68 Ga-FAPI-04 and 18 F-FDG PET/CT in Fumarate Hydratase-Deficient Renal Cell Carcinoma : A Prospective and Single-Center Study. Clin Nucl Med. 2024. PMID: 38991199. doi:10.1097/RLU.0000000000005367

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。